Competition is fierce with the emergence of Hanmi Pharmaceutical, which topped the PPI single-drug market. Hanmi Pharmaceutical's Esomezole Plus will launch in the highly competitive PPI+ antacids complex market. As Hanmi has a high market share with Esomezole, a single PPI drug, it is expected to cause significant changes in the current market composition if the complex is released.

The MFDS approved Hanmi Pharmaceutical's Esomezole Plus 40/350mg on the 22nd.

This product is a combination drug that combines "Esomeprazole magnesium trihydrate," a PPI-based gastroesophageal reflux disease treatment, and "Magnesium Hydroxide," a antacid. This is the first time that the ingredient has been c